The most recent Risperdal case settled before trial, but that doesn’t mean a global settlement is underway in the mass tort, according to a lawyer handing the litigation.
Moffat v. Janssen Pharmaceuticals, settled in May for an undisclosed amount. The suit involved claims that the company failed to warn users about the serious risks associated Risperdal, an antipsychotic drug.
According to an attorney handling the case, “The settlement was a “one-off,” and there are no talks under way for a settlement of larger litigation. Further, “There’s no global settlement talks. The Moffat case involved the Moffat case.”
Janssen released a statement that suggested global settlement talks are not under way.
Moffat is not the first Risperdal suit to conclude in a settlement. The case Walker v Janssen settled in May 2015 on the day trial was slated to start. Cases have been settled in litigation as on-offs and Moffat happens to be one of them.
The next wave of trials is will start later this year. While court records show 12 cases listed for trial in the Philadelphia Court. A.Y. v. Janssen Pharmaceuticals is not expected to settle but rather to serve as a bellwether trial which could shape a possible future global settlement.
Mass tort plaintiffs, including Moffat, contend the pharmaceutical giant was aware that those who took Risperdal were at an increased risk for gynecomastia, but failed to provide adequate warnings.